Drug intelligence / Profile preview

LYB002V14A

Development stage: Phase 1
Lead developer: Guangzhou Patronus Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LYB002V14A is a recombinant trivalent protein vaccine developed for COVID-19. It targets three SARS-CoV-2 variants (XBB.1, BQ.1.1, and the prototype strain) and is produced using Chinese hamster ovary (CHO) cells. The vaccine is administered intramuscularly as a booster following a primary series of inactivated COVID-19 vaccines in adults. Its mechanism of action involves inducing an immune response against the spike protein of SARS-CoV-2 to provide protection against infection[1][2][7]. Clinical trials are ongoing to assess its safety and immunogenicity.

Other names: LYB002V14LYB-002V14LYB 002V14Recombinant COVID-19 Trivalent (XBB.1+BQ.1.1+Prototype) Protein VaccineCHO Cell vaccine

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on LYB002V14A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB002V14A.

Explore the full profile